Psychiatric Autoimmunity: N-Methyl-d-Aspartate Receptor IgG and Beyond

Psychosomatics

Volumn 56, Issue 3, 2015, Pages 227-241

  Kruse, Jennifer L ^a   Lapid, Maria I ^a   Lennon, Vanda A ^a,b,c   Klein, Christopher J ^a,b   Toole, Orna O' ^b   Pittock, Sean J ^a,b   Strand, Edythe A ^b   Frye, Mark A ^a   McKeon, Andrew ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CELL ANTIGEN; CELL NUCLEUS ANTIGEN; CORTICOSTEROID; CYTOPLASMIC ANTIGEN; GLUTAMATE DECARBOXYLASE 65; IMMUNOGLOBULIN G; ION CHANNEL; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SYNAPSE RECEPTOR; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ADULT; AGED; ALLERGIC ENCEPHALITIS; ANTIBODY SPECIFICITY; ANXIETY DISORDER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD STORAGE; CATATONIA; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DISORIENTATION; FEMALE; HOSPITAL PATIENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL RECORD REVIEW; MENTAL DISEASE; MIDDLE AGED; PREDICTIVE VALUE; PSYCHIATRY; PSYCHOSIS; SEROLOGY; SERUM; SUICIDE; SYMPTOM; ADOLESCENT; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; BIPOLAR DISORDER; CASE CONTROL STUDY; DEPRESSION; HEBEPHRENIA; IMMUNOLOGY; PSYCHOLOGY; SUICIDAL IDEATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; ANXIETY DISORDERS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIPOLAR DISORDER; CALCIUM CHANNELS, N-TYPE; CALCIUM CHANNELS, P-TYPE; CALCIUM CHANNELS, Q-TYPE; CASE-CONTROL STUDIES; CATATONIA; DEPRESSIVE DISORDER; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MENTAL DISORDERS; MIDDLE AGED; POTASSIUM CHANNELS, VOLTAGE-GATED; PSYCHOTIC DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA, DISORGANIZED; SUICIDAL IDEATION; YOUNG ADULT;

EID: 84929154102     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2015.01.003     Document Type: Article

References (42)

1. McKeon A., Lennon V.A., Pittock S.J. Immunotherapy-responsive dementias and encephalopathies. Continuum (Minneap Minn) 2010, 16(2):80-101.
2. Benros M.E., Waltoft B.L., Nordentoft M., et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. J Am Med Assoc Psychiatry 2013, 70(8):812-820.
3. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010, 12(6):638-646.
4. Kupka R.W., Nolen W.A., Post R.M., et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002, 51(4):305-311.
5. Padmos R.C., Bekris L., Knijff E.M., et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry 2004, 56(7):476-482.
6. Eaton W.W., Byrne M., Ewald H., et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006, 163(3):521-528.
7. Bocchetta A., Tamburini G., Cavolina P., Serra A., Loviselli A., Piga M. Affective psychosis, Hashimoto[U+05F3]s thyroiditis, and brain perfusion abnormalities: case report. Clin Pract Epidemiol Ment Health 2007, 3:31.
8. Mussig K., Bartels M., Gallwitz B., Leube D., Haring H.U., Kircher T. Hashimoto[U+05F3]s encephalopathy presenting with bipolar affective disorder. Bipolar Disord 2005, 7(3):292-297.
9. Tomer Y., Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992, 10(4):391-393.
10. Liu C.Y., Tseng M.C., Lin P.H. Encephalopathy associated with autoimmune thyroid disease (Hashimoto[U+05F3]s thyroiditis) presenting as depression: a case report. Gen Hosp psychiatry 2011, 33(6):e7-e9. 641.
11. McKeon A., Pittock S.J. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011, 122(4):381-400.
12. Dalmau J., Gleichman A.J., Hughes E.G., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7(12):1091-1098.
13. Kruse J.L., Jeffrey J.K., Davis M.C., Dearlove J., Ishak W.W., Brooks J.O. Anti-N-methyl-d-aspartate receptor encephalitis: a targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management. Ann Clin Psychiatry 2014, 26(2):111-119.
14. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009, 110(1-3):1-23.
15. Titulaer M.J., McCracken L., Gabilondo I., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12(2):157-165.
16. Weissman M.M., Bland R.C., Canino G.J., et al. Cross-national epidemiology of major depression and bipolar disorder. J Am Med Assoc 1996, 276(4):293-299.
17. Kayser M.S., Titulaer M.J., Gresa-Arribas N., Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. J Am Med Assoc Neurol 2013, 70(9):1133-1139.
18. Zandi M.S., Irani S.R., Lang B., et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011, 258(4):686-688.
19. Masdeu J.C., Gonzalez-Pinto A., Matute C., et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am J Psychiatry 2012, 169(10):1120-1121.
20. McKeon A., Lennon V.A. NMDAR encephalitis: which specimens, and the value of values. Lancet Neurol 2014, 13(2):133-135.
21. Somers K.J., Lennon V.A., Rundell J.R., et al. Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci 2011, 23(4):425-433.
22. Flanagan E.P., McKeon A., Lennon V.A., et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 2010, 85(10):881-897.
23. Quek A.M., Britton J.W., McKeon A., et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012, 69(5):582-593.
24. O'Toole O., Lennon V.A., Ahlskog J.E., et al. Autoimmune chorea in adults. Neurology 2013, 80(12):1133-1144.
25. McKeon A., Lennon V.A., LaChance D.H., Klein C.J., Pittock S.J. Striational antibodies in a paraneoplastic context. Muscle Nerve 2013, 47(4):585-587.
26. Klein C.J., Lennon V.A., Aston P.A., et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. J Am Med Assoc Neurol 2013, 70(2):229-234.
27. McKeon A., Lennon V.A., Lachance D.H., Fealey R.D., Pittock S.J. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009, 66(6):735-741.
28. Pittock S.J., Yoshikawa H., Ahlskog J.E., et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006, 81(9):1207-1214.
29. Davison K. Autoimmunity in psychiatry. Br J Psychiatry 2012, 200(5):353-355.
30. Kayser M.S., Kohler C.G., Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010, 167(9):1039-1050.
31. Graus F., Boronat A., Xifro X., et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010, 74(10):857-859.
32. Lee S.W., Donlon S., Caplan J.P. Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) or Hashimoto[U+05F3]s encephalopathy: a case and review. Psychosomatics 2011, 52(2):99-108.
33. Yu Z., Kryzer T.J., Griesmann G.E., Kim K., Benarroch E.E., Lennon V.A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49(2):146-154.
34. Gresa-Arribas N., Titulaer M.J., Torrents A., et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014, 13(2):167-177.
35. Hammer C., Stepniak B., Schneider A., et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2014, 19(10):1143-1149.
36. Lancaster E., Leypoldt F., Titulaer M.J., et al. IgG antibodies to the NMDA receptor are distinct from IgA and IgM responses. Ann Neurol 2015, 77(1):183.
37. Titulaer M.J., Dalmau J. Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia: a theory with unproven links. Molec Psychiatry 2014, 19(10):1054.
38. Hacohen Y., Wright S., Waters P., et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2013, 84(7):748-755.
39. Quek A.M., McKeon A., Lennon V.A., et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012, 69(8):1039-1043.
40. Titulaer M.J., McCracken L., Gabilondo I., et al. Late-onset anti-NMDA receptor encephalitis. Neurology 2013, 81(12):1058-1063.
41. McKeon A. Immunotherapeutics for autoimmune encephalopathies and dementias. Curr Treat Options Neurol 2013, 15(6):723-737.
42. Kuppuswamy P.S., Takala C.R., Sola C.L. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. Gen Hosp Psychiatry 2014, 36(4):388-391.